Downloads: 133

Files in This Item:
File Description SizeFormat 
journal.pone.0136981.pdf1.24 MBAdobe PDFView/Open
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTakahara, Kiyoshija
dc.contributor.authorInamoto, Teruoja
dc.contributor.authorMinami, Koichiroja
dc.contributor.authorYoshikawa, Yukija
dc.contributor.authorTakai, Tomoakija
dc.contributor.authorIbuki, Naokazuja
dc.contributor.authorHirano, Hajimeja
dc.contributor.authorNomi, Hayahitoja
dc.contributor.authorKawabata, Shinjija
dc.contributor.authorKiyama, Satoshija
dc.contributor.authorMiyatake, Shin Ichija
dc.contributor.authorKuroiwa, Toshihikoja
dc.contributor.authorSuzuki, Minoruja
dc.contributor.authorKirihata, Mitsunorija
dc.contributor.authorAzuma, Haruhitoja
dc.contributor.alternative鈴木, 実ja
dc.date.accessioned2016-06-09T02:24:43Z-
dc.date.available2016-06-09T02:24:43Z-
dc.date.issued2015-09-01ja
dc.identifier.issn1932-6203ja
dc.identifier.urihttp://hdl.handle.net/2433/214549-
dc.description.abstract[Purpose] Boron neutron capture therapy (BNCT) is a selective radiation treatment for tumors that preferentially accumulate drugs carrying the stable boron isotope, 10B. BNCT has been evaluated clinically as an alternative to conventional radiation therapy for the treatment of brain tumors, and more recently, recurrent advanced head and neck cancer. Here we investigated the effect of BNCT on prostate cancer (PCa) using an in vivo mouse xenograft model that we have developed. [Materials and Methods] Mice bearing the xenotransplanted androgen-independent human PCa cell line, PC3, were divided into four groups: Group 1: untreated controls; Group 2: Boronophenylalanine (BPA); Group 3: neutron; Group 4: BPA-mediated BNCT. We compared xenograft growth among these groups, and the body weight and any motility disturbance were recorded. Immunohistochemical (IHC) studies of the proliferation marker, Ki-67, and TUNEL staining were performed 9 weeks after treatment. [Results] The in vivo studies demonstrated that BPA-mediated BNCT significantly delayed tumor growth in comparison with the other groups, without any severe adverse events. There was a significant difference in the rate of freedom from gait abnormalities between the BPA-mediated BNCT group and the other groups. The IHC studies revealed that BNCT treatment significantly reduced the number of Ki-67-positive cells in comparison with the controls (mean±SD 6.9±1.5 vs 12.7±4.0, p<0.05), while there was no difference in the number of apoptotic cells, suggesting that BPA-mediated BNCT reduced PCa progression without affecting apoptosis at 9 weeks post-treatment. [Conclusions] This study has provided the first preclinical proof-of-principle data to indicate that BPA-mediated BNCT reduces the in vivo growth of PCa. Although further studies will be necessary, BNCT might be a novel potential treatment for PCa.ja
dc.format.mimetypeapplication/pdfja
dc.language.isoengja
dc.publisherPublic Library of Scienceja
dc.rights© 2015 Takahara et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are creditedja
dc.titleThe anti-proliferative effect of boron neutron capture therapy in a prostate cancer xenograft modelja
dc.type.niitypeJournal Articleja
dc.identifier.jtitlePLOS ONEja
dc.identifier.volume10ja
dc.identifier.issue9ja
dc.relation.doi10.1371/journal.pone.0136981ja
dc.textversionpublisherja
dc.identifier.artnume0136981ja
Appears in Collections:Journal Articles

Show simple item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.